Vimian Group AB: Business Overview, Financials & Competitive Analysis
Vimian Group AB scores 7/10 on the AskCyborg Cyborg Score (Strong). Consolidator of fragmented veterinary solutions with strong growth momentum and defensive market exposure, suitable for investors seeking exposure to companion animal care commoditization. Vimian demonstrates solid execution with double-digit organic growth (15% in Q4 2024, 9% full year), strong profitability margins (25.4% adjusted EBITA), and strategic market positioning in.
What is Vimian Group AB's industry? Vimian Group AB (vimian.com) operates in Animal Health / Veterinary Services & Diagnostics. AskCyborg classifies Vimian Group AB under Animal Health / Veterinary Services & Diagnostics in its company registry.
Vimian Group is a global animal health company built around four core business segments: Specialty Pharma (Nextmune), Diagnostics (Indical), Veterinary Services (VetFamily), and MedTech (Movora). The company serves ve...
Cyborg Score thesis
Consolidator of fragmented veterinary solutions with strong growth momentum and defensive market exposure, suitable for investors...
Read the full analyst-debate transcript →Get the Latest Vimian Group AB Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeVimian Group AB Overview
Pro stress-test →Vimian Group is a global animal health company built around four core business segments: Specialty Pharma (Nextmune), Diagnostics (Indical), Veterinary Services (VetFamily), and MedTech (Movora). The company serves veterinary professionals, laboratories, and pet owners across 80+ markets through innovation-driven businesses addressing niche veterinary healthcare needs.
Strategic Profile
Pro stress-test →Vimian operates a diversified, acquisition-driven model that consolidates fragmented veterinary solutions into an integrated platform with shared infrastructure and capital. The company leverages its network access to 17,000+ veterinary clinics and laboratories to drive organic growth while expanding through strategic acquisitions into specialized niches like veterinary dentistry.
Competitive Landscape
Pro stress-test →Vimian competes in the fragmented global animal health market against larger diversified pharma companies (e.g., Boehringer Ingelheim, Zoetis) as well as specialized regional players. Its advantage lies in consolidating multiple niche businesses under one platform, enabling cross-selling, operational synergies, and technology leverage that pure-play competitors cannot match.
Industry Context
Vimian Group AB operates in Animal Health / Veterinary Services & Diagnostics.
Key facts
Founded: 2020 · Headquarters: Stockholm, Sweden · Employees: 1,200 · Revenue: EUR 374.8M (2024) · Market cap: $1.67B